Skip to main content

Table 3 Effect of silymarin with/without praziquantel on serum transforming growth factor-β1 and matrix metalloproteinase-2, 10 and 18 weeks post infection of mice with S.mansoni

From: Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis

Animal groups

Serum TGF-β1 (ng/ml)

Serum MMP-2 (ng/ml)

 

10 wks

18 wks

10 wks

18 wks

Uninfected (vehicle)

7.80 ± 0.69

7.98 ± 0.48

150.40 ± 18.17

181.00 ± 6.72

Infected (Vehicle)

†††

19.98 ± 2.37

†††

40.85 ± 1.41

††

265.43 ± 21.65

†††

374.00 ± 32.16

Infected+ PZQ

‡‡‡

11.32 ± 0.85

(43.34%)

†††‡‡‡

19.71 ± 0.24

(51.75%)

††‡

210.40 ± 8.13

(20.73%)

†††‡‡‡

226.83 ± 11.69

(39.35%)

Infected + silymarin

†††‡

13.44 ± 0.75

(32.73%)

†††

36.84 ± 1.44

(9.82%)

††

241.31 ± 36.25

(9.093%)

†††

283.80 ± 42.20

(24.12%)

Infected + PZQ + silymarin

‡‡‡§§

7.83 ± 0.65

(60.81%)

†††‡‡‡

18.29 ± 0.73

(55.23%)

‡‡§

165.33 ± 14.20

(37.71%)

‡‡‡§

187.60 ± 11.57

(49.84%)

  1. Data are presented as mean ± SEM (n = 8 in each group).
  2. Mice were administered praziquantel (PZQ; 500 mg/kg/day for 2 days) in the 7th week post infection (PI) and silymarin (750 mg/kg/day, 5 days/week for 6 weeks) at the 4th and 12th weeks PI for 6 weeks and were killed 10 and 18 weeks PI respectively. Numbers in parentheses indicate the percentage of reduction from infected (vehicle) group.
  3. †† Significantly different from uninfected (vehicle) group at P < 0.01 and ††† at P < 0.001. ‡ Significantly different from infected (vehicle) group at P < 0.05, ‡‡ at P < 0.01 and ‡‡‡ at P < 0.001. § Significantly different from infected treated with PZQ group at P < 0.05 and §§ at P < 0.01.